Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity
"The use of these drugs has exploded throughout industrialized countries and they have provided very significant benefits in many ways, but future discussions between a patient and their physician should include NAION as a potential risk," said Rizzo, the studys corresponding author
As of April 7, 2025, the court has not issued a final ruling on the preliminary injunction for Semaglutide, though a related case for Tirzepatide saw a denial on March 5, 2025 (US FDA to Hold off Action)
Oral GLP-1s for obesity saw a recent setback when in April (April 2025), Pfizer announced that it was discontinuing development of danuglipron, an oral GLP-1 receptor agonist, which was being investigated for chronic weight management, due to potential liver toxicity
Safe Consumption and Potential Risks of Brazil Nuts Whilst Brazil nuts can be part of a healthy diet, their extraordinarily high selenium content necessitates careful attention to portion size
Amid this landscape of so-called shortcuts for fixing low T, one controversial idea has emerged: can using nicotine actually boost testosterone in men